TBPH
Theravance Biopharma Inc
NASDAQ: TBPH · HEALTHCARE · BIOTECHNOLOGY
$16.52
-2.88% today
Updated 2026-05-11
Market cap
$876.78M
P/E ratio
7.63
P/S ratio
7.99x
EPS (TTM)
$2.23
Dividend yield
—
52W range
$8 – $21
Volume
0.6M
WallStSmart proprietary scores
52
out of 100
Grade: C
Hold
Investment rating
7.3
Growth
B+7.0
Quality
B+6.5
Profitability
B8.3
Valuation
A4/9
Piotroski F-Score
Moderate
-2.6
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →198 stocks currently score above 75
Price targets
Analyst target
$17.20
+4.12%
12-Month target
$15.29
-7.45%
Intrinsic (DCF)
$63.35
Margin of safety
+69.20%
0 Strong Buy3 Buy4 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 104.30% — above average
+ ROE 50.20% — strong efficiency
+ Free cash flow $73.28M — positive
+ Revenue growth 15.00% QoQ
+ 69.20% below intrinsic value
Risks
- Altman Z -2.61 — distress zone
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $51.35M | $57.42M | $64.38M | $107.46M | $109.78M |
| Net income | $872.13M | $-55.19M | $-56.42M | $105.89M | $-4.93M |
| EPS | — | — | — | — | $2.23 |
| Free cash flow | $-187.56M | $-29.48M | $-11.87M | $238.50M | $73.28M |
| Profit margin | 1,698.54% | -96.11% | -87.63% | 98.54% | 104.30% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-01 | WINNINGHAM, RICK E | Buy | 75,000 | — |
| 2026-04-01 | SAWAF, AZIZ | Buy | 37,500 | — |
| 2026-04-01 | GRIMAUD, BRETT A. | Buy | 37,500 | — |
Peer comparison
Smart narrative
Theravance Biopharma Inc trades at $16.52. representing a P/E of 7.63x trailing earnings. Our Smart Value Score of 52/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -2.61, it sits in the distress. TTM revenue stands at $109.78M. with profit margins at 104.30%. Our DCF model estimates intrinsic value at $63.35.
Frequently asked questions
What is Theravance Biopharma Inc's stock price?
Theravance Biopharma Inc (TBPH) trades at $16.52.
Is Theravance Biopharma Inc overvalued?
Smart Value Score 52/100 (Grade C, Hold). DCF value $63.35.
What is the price target of Theravance Biopharma Inc (TBPH)?
The analyst target price is $17.20, representing +4.1% upside from the current price of $16.52.
What is the intrinsic value of Theravance Biopharma Inc (TBPH)?
Based on our DCF model, intrinsic value is $63.35, a +69.2% margin of safety versus $16.52.
What is the future stock price of TBPH by 2030?
Our revenue-driven model estimates Theravance Biopharma Inc could reach $21.22 by 2030, based on historical CAGR, margin trends, and capped P/E multiples.
What is Theravance Biopharma Inc's revenue?
TTM revenue is $109.78M.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
-2.61 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio7.99x
ROE50.20%
Beta0.19
50D MA$15.76
200D MA$16.06
Shares out0.05B
Float0.02B
Short ratio—
Avg volume0.6M
Performance
1 week+1.67%
1 month+4.04%
3 months-12.32%
YTD-9.09%
1 year—
3 years—
5 years—